Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
Open Access
- 2 November 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 225 (1), 30-33
- https://doi.org/10.1093/infdis/jiab556
Abstract
A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against covid-19 infection. Of nearly one million members receiving two doses of BNT162b2 in Jan-Feb 2021, infection rates (based on PCR results) were compared between those who received a third dose with those who did not during August-October 2021 (max: 70 days). Crude VE was 92.9% (95% CI:92.6-93.2%) and adjusted VE was 89.1% (95% CI:87.5-90.5%). We conclude that the third dose provides added protection against COVID-19 infection for those vaccinated six months ago.Keywords
This publication has 7 references indexed in Scilit:
- Protection of BNT162b2 Vaccine Booster against Covid-19 in IsraelThe New England Journal of Medicine, 2021
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studyThe Lancet, 2021
- COVID-19 vaccine impact in Israel and a way out of the pandemicThe Lancet, 2021
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination SettingThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Covid-19: FDA panel votes to authorise Pfizer BioNTech vaccinePublished by BMJ ,2020